GRAIL to Unveil 174,000-Patient Galleri Trial Data at 2026 ASCO Meeting
GRAIL will unveil expanded NHS-Galleri results from 142,000 participants and full PATHFINDER 2 data from 32,000 evaluable subjects at the May 29–June 2, 2026 ASCO Annual Meeting in Chicago. Combined enrollment of over 174,000 participants underscores Galleri’s clinical rigor and potential to shift cancer detection earlier.
1. ASCO Presentation Schedule
GRAIL will present two late-breaking abstracts and one poster on the Galleri multi-cancer early detection test at the 2026 ASCO Annual Meeting in Chicago, May 29–June 2. Sessions include oral presentations of NHS-Galleri (LBA100) on May 30 at 8:12 am CDT, PATHFINDER 2 (LBA10509) on May 31 at 9:45 am CDT, and a poster on private practice adoption on June 1.
2. NHS-Galleri Trial Expansion
The NHS-Galleri trial enrolled over 142,000 participants aged 50–77 across England in a randomized controlled design comparing annual Galleri screening plus standard of care against standard screening alone. Initial topline data showed a reduction in late-stage cancer diagnoses and an increased overall cancer detection rate.
3. PATHFINDER 2 Final Results
PATHFINDER 2, conducted under an FDA-approved investigational device exemption, comprises more than 32,000 evaluable participants with no clinical suspicion of cancer, making it the largest North American MCED interventional study. The complete dataset will assess Galleri’s safety profile, performance metrics and ability to detect cancers early in an intended-use population.